logo

Press Releases

    • 27 APR 2022

    PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the management team will be attending the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) held April 27-30, 2022, in Barcelona, Spain.

    Read more →
    • 19 APR 2022

    PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

    LAS VEGAS, NV, April 19, 2022 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the empty capsule material that comprises its pancreatic cancer clinical trial product candidate does not cause systemic toxicity. PharmaCyte’s

    Read more →
    • 13 APR 2022

    PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that PharmaCyte has decided to accelerate preparations for the start of its Phase 2b clinical trial in locally advanced, inoperable pancreatic (LAPC) using its CypCapsTM clinical trial

    Read more →
    • 05 APR 2022

    PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

    LAS VEGAS, NV, April 5, 2022 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the appointment of Dr. Matthias Löhr to PharmaCyte’s Board of Directors. PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “PharmaCyte

    Read more →
    • 22 MAR 2022

    PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed a 24-month product stability study required by the U.S. Food and Drug Administration (FDA) for its clinical trial product candidate, CypCaps™. The

    Read more →
    • 16 MAR 2022

    PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

    LAS VEGAS, NV, March 16, 2022 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the financial and operational results for its third quarter ended January 31, 2022, and provided an overview of recent operational

    Read more →
    • 22 FEB 2022

    PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the results of an additional, more finely detailed, analysis of the integration site of the cytochrome P450 2B1 gene from the augmented HEK293 cell clone that

    Read more →
    • 14 FEB 2022

    PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

    LAS VEGAS, NV February 14, 2022 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today provided an update on PharmaCyte’s activities to lift the U.S. Food and Drug Administration’s (FDA) clinical hold on PharmaCyte’s treatment for

    Read more →
    • 06 JAN 2022

    PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference. The Conference is being held virtually on January 10-13, 2022. During

    Read more →
    • 04 JAN 2022

    PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the empty capsule material that makes up PharmaCyte’s CypCaps® pancreatic cancer product candidate is not toxic for the encapsulated cells inside the CypCaps. PharmaCyte’s Chief Executive

    Read more →